PTC Therapeutics Faces Setback on Translarna Approval

PTC Therapeutics announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has upheld its negative stance on renewing the conditional marketing authorization for Translarna, a treatment for Duchenne muscular dystrophy.